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Heart failure has received much publicity in the last
five years. In all western countries, the numbers of
patients admitted to hospital with heart failure is
rising sharply. There is now widespread agreement
about the poor prognosis, which is worse than many
forms of cancer (1). Heart failure has also become,
rather belatedly, a topic of considerable interest for
cardiologists. As well as new drugs available, there
are increasingly sophisticated procedures involving
biventricular pacing and the use of defibrillators
which, though costly, can significantly improve
prognosis in certain patient groups (2).
For internists, however, heart failure has always
been an integral part of treating an elderly
population. Many chronic disorders – hyper-
tension, diabetes, and chronic airways disease –
are associated with heart failure, which needs to
be treated actively alongside the presenting
condition. And there are now many new treatments
available, which both alleviate the symptoms of
the condition and improve prognosis.
This article will touch briefly on new aspects of
the diagnosis and treatment of heart failure and the
challenges in implementing them to the patient’s
best advantage.
Diagnosis
In order to identify and treat patients with heart
failure one must have a correct diagnosis. For many
years the key investigation, and the one that has
been used in most epidemiological studies and
therapeutic trials, is the finding of impaired left
ventricular function on echocardiography.
While impaired left ventricular function is
undoubtedly a highly important marker of reduced
prognosis and the likelihood of developing heart
failure, there are some remaining uncertainties. For
instance, by no means all patients with left
ventricular dysfunction develop overt heart failure
(with fluid retention, pulmonary oedema etc.) and
amongst hospital admissions there are now several
large surveys showing up to 40% of patients with
overt heart failure admitted to hospital have
apparently normal left ventricular systolic function
(3). This is often explained by the presence of
diastolic dysfunction, a subject that remains
controversial even within cardiological circles.
For the internist, echocardiography is useful if
available, but heart failure can often be excluded by
the presence of a normal ECG and chest x-ray. Where
diagnostic uncertainty remains, brain naturetic peptide
(BNP) may be the answer. This peptide, like atrial
naturetic peptide, is elevated in heart failure and is now
readily measured in a bedside assay. Several large
surveys have now shown this to be a valuable diag-
nostic tool in the clinical arena (4). In the emergency
room, raised BNP correctly identified the highest risk
group and allowed more focused therapy with
improved results. The measurement of BNP is now being
used in other settings and it may in due course supplant
echocardiography as the gold standard for the
diagnosis of heart failure. Key issues, however, remain
particularly about sensitivity and specificity. As the test
is extended more widely, one can reasonably expect
more false positives and false negatives to appear.
In practice, the clinical diagnosis of overt heart
failure is usually not difficult for most internists. Signs
of fluid retention on a background of known cardiac
disease, or diseases such as hypertension or
diabetes, are usually an indication for therapy with
diuretics and ACE inhibitors in any case. Given the
poor prognosis of heart failure, it is probably best
to over-diagnose rather than under-diagnose the
condition and initiate appropriate therapy.
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New Treatments
Following on the landmark studies with ACE
inhibitors in the eighties, the nineties have seen a
succession of studies with beta blockers, angiotensin
receptor blockers (ARB’s), spironolactone and the
new BNP antagonists.
• Beta-blockers
Although metoprolol has been in use in Scandi-
navian countries for many years in patients with
heart failure, its widespread use only came with
further large scale studies with metoprolol,
carvedilol and bisoprolol. All have shown reduced
hospitalisation, improved prognosis and some
improved quality of life and LV function (5).
After many years of being taught from under-
graduate days that beta blockers are contra-
indicated in heart failure it has taken cardiologists
and internists some time to come to terms with
these findings, with several studies showing
considerable under-use of beta blockers in clinical
practice.
• Angiotensin receptor blockers (ARB’s)
In the ELITE1 study, losartan showed some survi-
val benefit over captopril, but this was not
substantiated in the larger ELITE2 study (6).
Nevertheless, losartan was well tolerated and was
not significantly inferior to captopril in this study.
The VALHEFT study (7) has also shown additional
benefit when valsartan is added to an ACE inhibitor
in heart failure and there are a series of ongoing
studies with ARB’s that may well substantiate their
use in this condition. In the meantime, many
physicians use losartan as an alternative to ACE
inhibitors when intolerance develops, especially
from cough (though it must be remembered that a
small proportion of patients with ACEI cough may
do the same with ARB’s).
• Spironolactone
This is an old drug given a new lease of life by the
RALES study (8). This showed both symptomatic
and prognostic benefit in patients with severe heart
failure (class 3/4) already established on treatment
with diuretics, digoxin and ACE inhibitors. There
had been concern that the combination of an ACE
inhibitor and spironolactone might lead to
deterioration in renal function and hyperkalaemia
and although close monitoring is required, most
patients appeared to tolerate this combination well
with few requiring discontinuation of the drug for
metabolic or other reasons. It is certainly one of the
easiest of the newer drug treatments to implement
and is widely applicable during both hospital and
ambulatory practice.
• BNP/ANP antagonists
The increased recognition that raised naturetic
peptides are important in the pathogenesis of heart
failure has led to the development of new agents,
which are showing some promise. Nesiritide is now
licensed in the US and available in a number of
European countries and shows promise in treatment
of acute pulmonary oedema (9). Its precise role in
the treatment of both acute and chronic heart failure
yet remains to be determined.
Implementation
At one time, patients with heart failure were treated
with digoxin and diuretics with little monitoring
or follow-up. Given the current armamentarium
of drugs available, a much more structured
approach is necessary, particularly as the newer
drugs all require careful dose titration. This is the
sort of situation that lends itself well to protocol-
driven policies. There is an excellent example of
such policies being effective from the Italian
Group(10). Physicians, cardiologists and family
doctors agreed protocol to implement treatment
with beta-blockers and have been very successful
in doing so. They recently reported that from a
low baseline of 25% prescribed beta-blockers,
this rose to 48% over a 12 month period. This is a
model that needs to be applied elsewhere if we
are to achieve all the benefits that current
therapeutic advances promise.
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Liigesehaiguste esinemissagedus on suur ja
osteoartroos (edaspidi artroos) on kujunemas kõige
sagedasemaks haiguseks rahvastikus. Suur-
britannias on 1,3–1,75 miljonit artroosihaiget.
Prantsusmaal saab artroosi diagnoosi 6 miljonit
inimest aastas (1).
Eestis on reumatoloogilise esmashaigestumise
sagedus kõikide haigusklasside arvestuses 100 000
inimese kohta 4. kohal (2). Luu-lihaskonnahaiguste
sageduse kasv Eestis on valdavalt seotud artroosi
sagedasema diagnoosimisega. Nii registreeriti
2001. a artroosikoodiga (M 15–19) 14 039 uut
haiget (naiste-meeste suhe 2 : 1), mis on ligi 3000
võrra enam kui 1999. a. Möödunud sajandivahe-
tusel olid Eestis lihaskonna- ja sidekoehaigused
esmase vaegurluse põhjuseks 11%-l juhtudest (3).
Märkimisväärne on liigesevaevuste hulk perearstide
külastuse põhjusena. 2001. aastal oli Tartu ühe
perearstikeskuse andmetel (10 000 inimest) 11,2%
külastustest tingitud liigesehaigustest (4). Erinevalt
mitmest teisest haigusrühmast tekitavad liigese-
haigused vaegurlust, mis põhjustab füüsilist,
sotsiaalset ja materiaalset kahju (5).
Artroos on klassikaliseks haiguse näiteks, mis
piinab ja invaliidistab, olemata eluohtlik. Sellest
tõvest tingitud terviseprobleemid ei põhjusta
üldjuhul eluea lühenemist. Rahvastikus esineb
ar troosi 10–20%. Haiguse diagnoosimine
sageneb aasta-aastalt, seda põhjendatakse kesk-
mise eluea kasvu ja vanemaealiste osakaalu
Artroos – kas arstid saavad aidata?
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